[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430688":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":58,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (data collection)",null,"Patients medical records are reviewed for details about CAR-T and RT treatment and acute and late toxicities, disease outcomes such as any events related to local or distant disease progression, survival, and cause of death if available. Patients' imaging scan data is collected at baseline, within 2 months of the first treatment of RT or CAR-T, and at 3, 6, 12 months, and then annually for 5 years after RT completion.",[13,14],"Other: Data Capture","Other: Electronic Medical Record",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"Data Capture","Treatment related data is collected",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Electronic Medical Record","Medical records are reviewed",[9],[25,26,27],"Computer Based Patient Record","EMR","EMR (electronic medical record)",[29],{"name":30,"affiliation":5,"role":31},"Penny Q Fang","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Penny Q Fang, MD","CONTACT","713-563-2345","pfang@mdanderson.org",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-95.36327,29.76328,{"lat":51,"lon":50},[54,57],{"name":55,"role":35,"phone":56,"phoneExt":10,"email":37},"Penny Q. Fang, MD","832-260-1389",{"name":55,"role":31,"phone":10,"phoneExt":10,"email":10},{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100430688","outcomes-after-chimeric-antigen-receptor-therapy-and-radiation-therapy-for-hematologic-malignancies-100430688",false,"NCT04888338","Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies","Outcomes After Chimeric Antigen Receptor Therapy (CAR-T) and Radiation Therapy (RT) for Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Treatment with or intention to treat with radiation therapy, standard-of-care CAR-T cell therapy and\u002For standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy","ALL","18 Years",{"count":70,"type":71},100,"ESTIMATED","OBSERVATIONAL","This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.",[75],"Hematopoietic and Lymphoid Cell Neoplasm","2026-04-13",{"date":78,"type":79},"2026-04-16","ACTUAL",{"date":81,"type":79},"2021-04-10",{"date":83,"type":71},"2026-11-14",{"name":5,"class":6},1]